NasdaqGS:BMRN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. More Details


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has BioMarin Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BMRN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.1%

BMRN

-2.2%

US Biotechs

-0.8%

US Market


1 Year Return

14.8%

BMRN

35.6%

US Biotechs

13.8%

US Market

Return vs Industry: BMRN underperformed the US Biotechs industry which returned 35.6% over the past year.

Return vs Market: BMRN exceeded the US Market which returned 13.8% over the past year.


Shareholder returns

BMRNIndustryMarket
7 Day0.1%-2.2%-0.8%
30 Day1.3%-0.3%-5.7%
90 Day-37.3%-1.6%8.6%
1 Year14.8%14.8%38.0%35.6%16.4%13.8%
3 Year-17.4%-17.4%15.6%10.0%36.9%27.8%
5 Year-29.6%-29.6%19.3%11.0%85.0%64.2%

Price Volatility Vs. Market

How volatile is BioMarin Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioMarin Pharmaceutical undervalued compared to its fair value and its price relative to the market?

27.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BMRN ($77.39) is trading below our estimate of fair value ($106.66)

Significantly Below Fair Value: BMRN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BMRN is poor value based on its PE Ratio (113.9x) compared to the US Biotechs industry average (25x).

PE vs Market: BMRN is poor value based on its PE Ratio (113.9x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

PEG Ratio: BMRN is poor value based on its PEG Ratio (7x)


Price to Book Ratio

PB vs Industry: BMRN is overvalued based on its PB Ratio (4.3x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is BioMarin Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?

16.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMRN's forecast earnings growth (16.3% per year) is above the savings rate (2.2%).

Earnings vs Market: BMRN's earnings (16.3% per year) are forecast to grow slower than the US market (22.9% per year).

High Growth Earnings: BMRN's earnings are forecast to grow, but not significantly.

Revenue vs Market: BMRN's revenue (18.4% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: BMRN's revenue (18.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BMRN's Return on Equity is forecast to be low in 3 years time (15.2%).


Next Steps

Past Performance

How has BioMarin Pharmaceutical performed over the past 5 years?

42.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BMRN has a large one-off gain of $69.4M impacting its June 30 2020 financial results.

Growing Profit Margin: BMRN became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: BMRN has become profitable over the past 5 years, growing earnings by 42.2% per year.

Accelerating Growth: BMRN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BMRN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: BMRN's Return on Equity (3.8%) is considered low.


Next Steps

Financial Health

How is BioMarin Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: BMRN's short term assets ($2.6B) exceed its short term liabilities ($813.3M).

Long Term Liabilities: BMRN's short term assets ($2.6B) exceed its long term liabilities ($1.3B).


Debt to Equity History and Analysis

Debt Level: BMRN's debt to equity ratio (44.6%) is considered high.

Reducing Debt: BMRN's debt to equity ratio has increased from 28.1% to 44.6% over the past 5 years.

Debt Coverage: BMRN's debt is not well covered by operating cash flow (9.7%).

Interest Coverage: Insufficient data to determine if BMRN's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is BioMarin Pharmaceutical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMRN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Jean-Jacques Bienaimé (67 yo)

15.33yrs

Tenure

US$18,405,856

Compensation

Mr. Jean-Jacques Bienaimé, MBA, serves as a Member of Strategic Advisory Board at Longwood Fund. He has been the Chief Executive Officer of Biomarin Pharmaceutical Inc. since June 2005. He served as Direct ...


CEO Compensation Analysis

Compensation vs Market: Jean-Jacques's total compensation ($USD18.41M) is above average for companies of similar size in the US market ($USD11.36M).

Compensation vs Earnings: Jean-Jacques's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jean-Jacques Bienaimé
Chairman & CEO15.33yrsUS$18.41m0.30%
$ 42.3m
Jeffrey Ajer
Executive VP & Chief Commercial Officer7.92yrsUS$6.34m0.035%
$ 4.9m
Henry Fuchs
President of Worldwide Research & Development3.92yrsUS$7.02m0.057%
$ 8.0m
Brian Mueller
Executive VP & CFO0.67yrno data0.016%
$ 2.3m
Andrea Acosta
Group VP & Chief Accounting Officer0.25yrno data0.00075%
$ 105.3k
C. Guyer
CTO and Executive VP of Global Manufacturing & Technical Operations0.33yrno datano data
Lon Cardon
Chief Scientific Strategy Officerno datano datano data
Traci McCarty
Vice President of Investor Relationsno datano datano data
George Davis
Executive VP16.67yrsUS$2.71m0.036%
$ 5.1m
Philip Scalzo
Senior VP & Chief Compliance Officerno datano datano data
Brinda Balakrishnan
Group Vice President of Corporate & Business Developmentno datano datano data
Amy Wireman
Senior Vice President of Human Resources1.67yrsno datano data

2.8yrs

Average Tenure

53.5yo

Average Age

Experienced Management: BMRN's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jean-Jacques Bienaimé
Chairman & CEO15.33yrsUS$18.41m0.30%
$ 42.3m
Richard Meier
Lead Independent Director5.25yrsUS$510.52k0.042%
$ 5.9m
Michael Grey
Independent Director14.75yrsUS$465.52k0.021%
$ 3.0m
David E. Pyott
Independent Director4.67yrsUS$454.90k0.015%
$ 2.0m
Elaine Heron
Independent Director18.17yrsUS$477.02k0.024%
$ 3.3m
V. Lawlis
Independent Director13.25yrsUS$458.27k0.0080%
$ 1.1m
Willard Dere
Independent Director4.17yrsUS$454.27k0.0050%
$ 696.1k
Dennis Slamon
Independent Director6.5yrsUS$454.27k0.0078%
$ 1.1m
Robert Hombach
Independent Director3yrsUS$471.90k0.0041%
$ 578.2k
Elizabeth Anderson
Independent Director1.17yrsUS$412.50kno data

5.3yrs

Average Tenure

67yo

Average Age

Experienced Board: BMRN's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BMRN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioMarin Pharmaceutical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioMarin Pharmaceutical Inc.
  • Ticker: BMRN
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$14.035b
  • Shares outstanding: 181.35m
  • Website: https://www.biomarin.com

Number of Employees


Location

  • BioMarin Pharmaceutical Inc.
  • 770 Lindaro Street
  • San Rafael
  • California
  • 94901
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMRNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 1999
BM8DB (Deutsche Boerse AG)YesCommon StockDEEURJul 1999
BMRNWBAG (Wiener Boerse AG)YesCommon StockATEURJul 1999
0HNCLSE (London Stock Exchange)YesCommon StockGBUSDJul 1999
BM8ETLX (Eurotlx)YesCommon StockITEURJul 1999
BMRN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJul 1999
B1MR34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 2 REPR 1 COMBRBRLJan 2020

Biography

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products inclu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 04:53
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.